BioTuesdays

Category - Markets

Recro Pharma

Roth starts Recro Pharma at buy

Roth Capital Partners has launched coverage of Recro Pharma (NASDAQ:REPH) with a “buy” rating and a $24 price target. The stock closed at $9.31 on Thursday. “The impetus for our buy rating on Recro shares is the upside...

Summit

Wainwright starts Summit Therapeutics at buy

H.C. Wainwright initiated coverage of Summit Therapeutics (NASDAQ:SMMT) with a “buy” rating and $26 price target. The stock closed at $5.50 on Thursday. Summit has two de-risked assets, with billion-dollar potential...

Aerie Pharmaceuticals

Stifel ups Aerie Pharma price target to $50

Stifel raised it price target for Aerie Pharmaceuticals (NASDAQ:AERI) to $50 from $40 after the company’s Roclatan eye drop hit all its endpoints with clinically meaningful results in a Phase 3 trial. The stock closed...

Vitae Pharmaceuticals

Stifel downgrades Vitae Pharma to hold

Stifel downgraded Vitae Pharmaceuticals (NASDAQ:VTAE) to “hold” from “buy” with a new price target of $21 after the company accepted a merger agreement from Allergan (NYSE:AGN) valued at $639-million or $21 a share. In...

ViewRay

BTIG starts ViewRay at buy

BTIG Research launched coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and $6 price target. The stock closed at $3.58 on Tuesday. MRIdian is the first commercial MRI guided radiation therapy treatment system...

novadaq

Scotiabank starts Novadaq at sector outperform

Scotiabank initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “sector outperform” rating and a one-year price target of $18.  The stock closed at $11.43 on Tuesday. Analyst Alan Ridgeway writes...

Mirna Therapeutics

Wainwright starts Mirna Therapeutics at buy

H.C. Wainwright initiated coverage of Mirna Therapeutics (NASDAQ:MIRN) with a ‘buy” rating and $6 price target, saying the company’s promising microRNA technology “could be a gift to long-term investors.” The stock was...

Cogentix Medical

Roth upgrades Cogentix Medical to buy

Roth Capital Partners upgraded Cogentix Medical (NASDQQ:CGNT) to “buy” from “neutral” and raised its price target to $2.20 from $1.25 after the company announced proposed equity financing and debt conversion...

Nabriva Therapeutics

Wainwright starts Nabriva Therapeutics at buy

H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday. Originally spun-off from Sandoz, Austria-based Nabriva has in...